Under the terms of the Funding Agreement, the Funder agreed to fund the legal fees and costs incurred by the Company in connection with the Litigation on and after March 1, 2020 on a non-recourse basis in return for a share of the litigation proceeds. Details of the Funding Agreement are available in the Form 8-K filed today.
BioCardia CEO Peter Altman, PhD, said, "This litigation financing gives BioCardia the wherewithal to pursue its claims in court. This preserves our investment focus on advancing our important cell therapy product pipeline to treat cardiovascular diseases, and the commercialization of our FDA-approved enabling device products."
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. In particular, the outcome and timing of litigation are uncertain. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
Media Contact:
Michelle McAdam, Chronic Communications, Inc.
Email: [email protected]
Phone: 310-902-1274
Investor Contact:
David McClung, Chief Financial Officer
Email: [email protected]
Phone: 650-226-0120
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
